http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3648782-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_028ce3147f0d780118f1f64d28a332a1 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-122 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-38 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2018-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_678f218e1c3fac1959b1bf4c68c71db3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d617407cc30dfc0d8196828901b8873 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5764852f3b8833d24b3963c22d5b2dc9 |
| publicationDate | 2020-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3648782-A2 |
| titleOfInvention | Use of ferruginin a (fga) compound as a chemotherapeutic gent and mapk pathway inhibitor due to biological activity thereof |
| abstract | The invention relates to use ferruginin A (FGA) compound that presents an effective cytotoxic activity in cancer chemotherapy as an anticancer agent and MAPK pathway inhibitor. The objective of the invention is to use Ferruginin A (FGA) compound that can be isolated from the bark of Harungana madagascariensis, as an anticancer agent and as MAPK pathway inhibitor at MCF-7 cells. The fact that Ferruginin A presents low effect on human normal skin fibroblasts, thus presents selective toxicity towards the cancer cells selective toxicity is exploited under the scope of the invention. |
| priorityDate | 2017-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 227.